[go: up one dir, main page]

BR9401185A - Processo para o tratamento de diabetes mellitus e composição de matéria - Google Patents

Processo para o tratamento de diabetes mellitus e composição de matéria

Info

Publication number
BR9401185A
BR9401185A BR9401185A BR9401185A BR9401185A BR 9401185 A BR9401185 A BR 9401185A BR 9401185 A BR9401185 A BR 9401185A BR 9401185 A BR9401185 A BR 9401185A BR 9401185 A BR9401185 A BR 9401185A
Authority
BR
Brazil
Prior art keywords
treatment
diabetes mellitus
matter
composition
administration
Prior art date
Application number
BR9401185A
Other languages
English (en)
Inventor
Dennis Edward Danley
Robert Alan Gelfand
Kieran Francis Geoghegan
Yesook Kim
William Joseph Lambert
Hong Qi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9401185A publication Critical patent/BR9401185A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Communication System (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9401185A 1993-04-07 1994-03-16 Processo para o tratamento de diabetes mellitus e composição de matéria BR9401185A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4413393A 1993-04-07 1993-04-07

Publications (1)

Publication Number Publication Date
BR9401185A true BR9401185A (pt) 1994-10-18

Family

ID=21930680

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9401185A BR9401185A (pt) 1993-04-07 1994-03-16 Processo para o tratamento de diabetes mellitus e composição de matéria

Country Status (18)

Country Link
EP (1) EP0619322B1 (pt)
JP (5) JPH072695A (pt)
KR (1) KR100186885B1 (pt)
CN (2) CN1311865C (pt)
AT (1) ATE314393T1 (pt)
AU (1) AU682328B2 (pt)
BR (1) BR9401185A (pt)
CA (1) CA2116478C (pt)
CZ (1) CZ296341B6 (pt)
DE (1) DE69434588T2 (pt)
ES (1) ES2255051T3 (pt)
HU (1) HU225496B1 (pt)
IL (1) IL108611A (pt)
NO (1) NO318804B1 (pt)
NZ (1) NZ250844A (pt)
PL (1) PL180697B1 (pt)
RU (1) RU2126264C1 (pt)
ZA (1) ZA94878B (pt)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JPH0682743A (ja) * 1992-09-04 1994-03-25 Sony Corp 強誘電性液晶組成物
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (en) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69529998D1 (de) * 1994-12-23 2003-04-24 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
DE19530865A1 (de) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
JP2001503963A (ja) * 1996-02-06 2001-03-27 イーライ・リリー・アンド・カンパニー 糖尿病治療
WO1997047323A2 (en) * 1996-06-11 1997-12-18 Zonagen, Inc. Chitosan drug delivery system
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
JP4754067B2 (ja) * 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
WO1999029336A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
DK1105460T3 (da) 1998-08-10 2010-02-08 Us Gov Health & Human Serv Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser deraf
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
CZ2001690A3 (cs) * 1998-08-28 2002-04-17 Eli Lilly And Company Způsob podávání inzulinotropních peptidů
CA2372214A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
IL149355A0 (en) * 1999-10-28 2002-11-10 Inst Neftechimicheskogo Sintez Polypeptide corporation
EP1396499A3 (en) * 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
ES2218381T3 (es) * 2000-01-27 2004-11-16 Eli Lilly And Company Procedimiento para solubilizar compuestos del peptido 1 de tipo glucagon.
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001228327A1 (en) * 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
EP1542712A2 (en) 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
WO2003018516A2 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
RU2332229C2 (ru) 2002-02-20 2008-08-27 Эмисфире Текнолоджис Инк. Способ введения молекул glp-1
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003268621B2 (en) * 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1585771A4 (en) * 2002-12-31 2006-11-29 Altus Pharmaceuticals Inc COMPLEXES OF PROTEIN CRYSTALS AND IONIC POLYMERS
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
WO2004078195A1 (ja) * 2003-03-07 2004-09-16 Ajinomoto Co., Inc. 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
HRP20050683A2 (en) * 2003-03-19 2006-07-31 Eli Lilly And Company Polyethylene glycol linked glp-1 compounds
TWI454465B (zh) 2003-06-03 2014-10-01 Melinta Therapeutics Inc 聯芳基雜環化合物及製法及其用途
RU2246964C1 (ru) * 2003-10-23 2005-02-27 Государственное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГОУВПО СибГМУ) Средство, обладающее гиполипидемическим, антиоксидантным и гипогликемическим действием, для лечения сердечно- сосудистых и эндокринных заболеваний и способ его применения
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
WO2005058252A2 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP1904525A4 (en) 2005-06-30 2009-10-21 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
NZ571862A (en) * 2006-04-13 2011-10-28 Ipsen Pharma Sas Pharmaceutical composition comprising HGLP-1, a zinc divalent metal ion and a solvent
WO2007124461A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CN102171244B (zh) * 2008-08-07 2015-05-13 益普生制药股份有限公司 糖依赖性胰岛素释放肽的类似物
AU2009280012B2 (en) * 2008-08-07 2012-12-06 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
EA020005B1 (ru) * 2008-08-07 2014-07-30 Ипсен Фарма С.А.С. Аналоги глюкозазависимого инсулинотропного полипептида
CN102281865B (zh) * 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
US20120157382A1 (en) 2010-12-21 2012-06-21 Siegfried Krimmer Pharmaceutical glp-1 compositions having an improved release profile
WO2012098187A1 (en) * 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102643339B (zh) * 2011-02-21 2014-04-09 天津药物研究院 一种glp-1类似物、制备方法及其应用
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MX2015008114A (es) 2012-12-21 2015-11-06 Sanofi Sa Derivados de exendina-4.
US9528648B2 (en) 2013-03-15 2016-12-27 Opw Fueling Components Inc. Breakaway assembly with relief valve
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CN113912673B (zh) * 2021-11-09 2024-02-09 河南省农业科学院 一种芝麻来源的低苦味ace抑制肽及其制备方法和应用
AU2023272483A1 (en) 2022-05-18 2024-12-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
WO1989003671A1 (fr) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Preparation a liberation entretenue
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
WO1990011296A1 (en) * 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
CA2073856C (en) * 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5069223A (en) * 1990-02-14 1991-12-03 Georgetown University Method of evaluating tissue changes resulting from therapeutic hyperthermia
PL166951B1 (pl) * 1990-06-15 1995-07-31 Schering Corp Sposób wytwarzania tetragonalnych krysztalów ludzkiej interleukiny-4 PL PL PL PL
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat

Also Published As

Publication number Publication date
CN1311865C (zh) 2007-04-25
HU225496B1 (en) 2007-01-29
DE69434588T2 (de) 2006-09-07
JP2001158749A (ja) 2001-06-12
CA2116478C (en) 2002-12-03
ES2255051T3 (es) 2006-06-16
HK1070589A1 (en) 2005-06-24
AU682328B2 (en) 1997-10-02
NO318804B1 (no) 2005-05-09
IL108611A0 (en) 1994-05-30
ZA94878B (en) 1995-08-10
CN1544084A (zh) 2004-11-10
HUT68525A (en) 1995-06-28
JPH072695A (ja) 1995-01-06
DE69434588D1 (de) 2006-02-02
JP4610503B2 (ja) 2011-01-12
AU5501694A (en) 1994-10-13
JP2010006841A (ja) 2010-01-14
JP5081213B2 (ja) 2012-11-28
PL180697B1 (pl) 2001-03-30
NO940436D0 (no) 1994-02-09
CZ296341B6 (cs) 2006-02-15
IL108611A (en) 2004-06-20
JP2004099621A (ja) 2004-04-02
ATE314393T1 (de) 2006-01-15
CZ27594A3 (en) 1995-05-17
RU2126264C1 (ru) 1999-02-20
JP2006213727A (ja) 2006-08-17
HU9400350D0 (en) 1994-05-30
CA2116478A1 (en) 1994-10-08
EP0619322A2 (en) 1994-10-12
CN1106698A (zh) 1995-08-16
CN1080123C (zh) 2002-03-06
NO940436L (no) 1994-10-10
NZ250844A (en) 1996-03-26
EP0619322B1 (en) 2005-12-28
EP0619322A3 (en) 1996-03-13
KR100186885B1 (ko) 1999-05-01

Similar Documents

Publication Publication Date Title
BR9401185A (pt) Processo para o tratamento de diabetes mellitus e composição de matéria
DK1364967T3 (da) Glucagonlignende, insulinetrope peptider, sammensætninger og metoder
EP0464022A4 (en) Insulinotropic hormone
AU3888893A (en) Use of a peptide
BR9714505A (pt) para o diabetes.
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
AR019818A1 (es) Un inmunoconjugado de miostatina.
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
IL72468A (en) Pharmaceutical composition for the treatment of diabetes mellitus comprising a combination of insulins
DK0635264T3 (da) Anti-østrogene 2-phenyl-3-aroylbenzothiazepiner som hypoglykæmiske midler
AU5446590A (en) Drugs (calcitonin gene-related peptides) for treating erectile dysfunctions
PT92148A (pt) Processo para a preparacao de pomada contendo colesterol para o tratamento topico de dermatoses
ES2056202T3 (es) Procedimiento para colorear el cabello con composiciones aminoalquil o aminohidroxialquil catecol.
CY1105254T1 (el) Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο
BR9107257A (pt) Composicao detergente enzimatrica,processo para o tratamento de uma protease,e,protease
BR9402818A (pt) Composto, composição, processo para estabilização de um material orgânico e uso
ES2131122T3 (es) Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
DK0607278T3 (da) Fremgangsmåde til forstærkning af tarmabsorption
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
BR9810142A (pt) Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
DK0482108T3 (da) Substituerede 2-imidazoliner samt fremstilling og anvendelse deraf
BR9001354A (pt) Composicao azeotropica e processo para limpeza de uma superficie solida
AU542310B2 (en) Glicentin related purified peptide having 30 amino acids
ECSP982591A (es) Nuevo metodo de tratamiento iv
IT1264562B1 (it) Composizione farmaceutica per l'applicazione topica di 17,b estradiolo nel trattamento della cheratocongiuntivite sicca

Legal Events

Date Code Title Description
EE Request for examination
EG Technical examination (opinion): publication of technical examination (opinion)
PC Transfer

Free format text: SCIOS INC (US)

FC Decision: refusal
CKFC Appeal: appeal against refusal
TE Change of address
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/605 (2006.01), A61K 38/00 (2006.0